A Phase 2, Open-Label, Multicenter Study of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)
A Phase 2, Open-Label, Multicenter Study of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)
The purpose of this study is to evaluate the effectiveness and safety of Arlocabtagene Autoleucel (BMS-986393) in participants with relapsed or refractory multiple myeloma.
Inclusion Criteria
Exclusion Criteria
Clinical.Trials@bms.com855-907-3286
Birmingham, Alabama 35294-3300, United States
205-934-1908
Los Angeles, California 90095, United States
San Francisco, California 94143, United States
Chapel Hill, North Carolina 27599-7305, United States
Columbus, Ohio 43210, United States
Philadelphia, Pennsylvania 19107, United States
San Antonio, Texas 78229, United States
Madison, Wisconsin 53792, United States
000-000-0000
310-829-5471
415-514-0768
720-754-4800
000-000-0000
201-310-8558
813-745-2475
502-608-5503
404-255-1930
312-505-1290
630-917-8956
913-588-6029
502-899-3366
617-724-4000
617-632-3000
855-776-0015
314-454-8304
732-209-5479
216-286-4441
646-962-6500
646-608-3712
617-842-6051
888-961-4156
570-423-0522
503-494-0896
917-698-4310
615-329-0570
917-913-9166
214-648-5906
713-792-6662
210-670-2313
801-408-3729
757-461-7084
206-606-1453
608-262-9317
+61295158031
+61736460818
0403374221
61392882698
4032202801
514-934-1934-31558
81528515511
+81-90-2102-4734
+81432227171
81752515740
8133400104